Several fluoroquinolone antibiotics have been associated with cardiac adverse effects, leading to the withdrawal of some of these agents from the market.
Cardiac side effects such as QT prolongation and torsades de pointes ( TdP ) have also been observed with fluoroquinolones currently on the market.
In order to evaluate the cardiac risk of fluoroquinolones as a class, and the comparative risk for each individual drug, researchers have conducted a systematic review, meta-analysis, and network meta-analysis.
MEDLINE, EMBASE and the Cochrane Library were searched, up to March 2018, for randomized controlled trials, cohort studies, and case–control studies that investigated the association between fluoroquinolone treatment and the risk of cardiovascular events and cardiovascular mortality.
Researchers have followed the PRISMA 2009 guidelines for data selection and extraction.
Thirteen studies were included in the analyses.
Fluoroquinolone use was associated with a statistically significant 85% increase in the risk for arrhythmia ( odds ratio [ OR ] 1.85; 95% confidence interval [ CI ] 1.22–2.81 ) and 71% increase in the risk for cardiovascular mortality ( OR 1.71; 95% CI 1.39–2.09 ).
Moxifloxacin ( Avelox ) ranked most likely to have the highest risk for arrhythmia ( P-score 0.99 ) and for cardiovascular mortality ( P-score 0.95 ) by network meta-analysis.
In conclusion, these findings have shown a significant association between fluoroquinolone use and an increased risk for arrhythmia and cardiovascular mortality.
Moxifloxacin ranked with the highest probability for cardiovascular adverse events.
Further study is required to determine how to reduce the risk for fluoroquinolone-associated cardiac toxicity. ( Xagena )
Gorelik, E., Masarwa, R., Perlman, A. et al Drug Saf 2018.doi.org/10.1007/s40264-018-0751-2